Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USV Primes German Base With Juta Acquisition

Executive Summary

USV is building on its play in Europe with the acquisition of Juta Pharma in Germany – a market that has been fostering generics alongside supporting innovative medicines.

You may also be interested in...



India’s USV Joins Line-Up For Biosimilar Neulasta In Europe

USV has joined the list of firms seeking clearance for biosimilar pegfilgrastim in Europe. Managing director Prashant Tewari says the company is “well geared” to address potential price competition and maintains that biosimilarity of USV’s pegfilgrastim with the innovator product has been established “satisfactorily”.

USV Seeks To Progress Oral Insulin In India

USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.

Deal 2: Lupin snaps up Temmler's products

Lupin has announced its second acquisition on the trot – this time an asset purchase deal concerning Temmler Pharma GmbH & Co's specialty product portfolio in Germany.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel